American Society of Clinical Oncology
225 Reinekers Lane
Suite 650
Alexandria
Virginia
22314
United States
Tel: 703-299-0150
Fax: 703-299-1044
Website: http://www.asco.org/
Email: asco@asco.org
2074 articles with American Society of Clinical Oncology
-
Novartis flexed its clinical muscles over the weekend, announcing results from multiple studies including different types of cancer and kidney disease.
-
Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual Meeting
6/4/2021
Survival benefit observed in two treatment settings of previously treated non-small lung cancer patients
-
With the 2021 American Society of Clinical Oncology Annual Meeting now in high gear, there is plenty of news. Here’s a look at just some of the most recent stories.
-
ImmVira will present the U.S. Clinical Phase I Study Results of MVR-T3011 via Intratumoral Administration at ASCO 2021
6/2/2021
ImmVira will present results from its clinical Phase I study of MVR-T3011 via intratumoral administration at the 2021 American Society of Clinical Oncology Annual Meeting on June 4-8, 2021 for the first time.
-
Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
5/19/2021
New data from across Eli Lilly and Company's oncology portfolio will be presented at the 2021 American Society of Clinical Oncology Annual Meeting, held June 4-8, 2021.
-
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
5/19/2021
Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel, at the American Society of Clinical Oncology congress.
-
The FDA further delays Iovance’s filing for its TIL therapy as it requests additional data on the treatment’s potency assays.
-
Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer
5/19/2021
Amcenestrant, an investigational oral selective estrogen receptor degrader (SERD), achieved an objective response rate of 34% and a clinical benefit rate of 74% in Phase 1 study (AMEERA-1) in combination with palbociclib
-
ASCO 2021 Showcases the Impact of Caris' Molecular Science Data in Advancing Cancer Care
5/18/2021
Over 20 studies to be presented at ASCO, featuring data from leading cancer research institutions across the U.S. in partnership with Caris Life Sciences, highlighting Caris' innovative technology and robust clinico-genomic database.
-
Syapse Showcases Real-World Mortality Data in American Society of Clinical Oncology’s JCO-CCI
4/9/2021
Study validates Syapse’ Composite Mortality Score methodology and its ability to overcome disparities driven by social determinants of health in the capture of mortality in the real-world setting.
-
New England Journal of Medicine Publishes Final Data for NUBEQA®(darolutamide) Plus Androgen Deprivation Therapy Showing a Statistically Significant Improvement in Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer
9/9/2020
The New England Journal of Medicine published the full overall survival results from the pre-specified final OS analysis of the Phase III ARAMIS trial for NUBEQA® in men with non-metastatic castration-resistant prostate cancer.
-
American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer
8/21/2020
Myriad Genetics, Inc., a global leader in molecular diagnostics and precision medicine, announced that the American Society of Clinical Oncology has exclusively included Myriad’s myChoice® CDx test in its new recommendations on the use of PARP inhibitors for the treatment and management of certain patients with advanced ovarian cancer.
-
The American Society of Clinical Oncology 2020 meeting was held virtually this year due to the COVID-19 pandemic. As usual, there were literally hundreds of abstracts, posters and presentations. Here’s a look at some of the highlights.
-
MiNA Therapeutics Presents Top Line Results from Phase Ib Study of MTL‑CEBPA in Combination with Sorafenib in Liver Cancer at 2020 ASCO Annual Meeting
5/29/2020
Observed clinical activity, including durable and complete tumour responses, suggests that MTL‑CEBPA may increase the effectiveness of sorafenib standard of care
-
Harpoon Therapeutics to Present Interim Clinical Data for TriTAC® HPN424 at the ASCO20 Virtual Scientific Program
5/22/2020
Management to host webcast and conference call to review interim Phase 1 data and provide a pipeline update at 4 p.m. ET /1 p.m. PT on May 29, 2020
-
BostonGene Announces Acceptance of Abstracts to the Annual Meeting of the American Society of Clinical Oncology 2020
5/19/2020
Abstracts Underscore the Results of Collaborations with Multiple Leading Cancer Centers in the United States
-
Kleo Pharmaceuticals to Present Preclinical Data Highlighting the Synergistic Potential of Kleo Asset KP1237 and Autologous NK Cells in the Treatment of Multiple Myeloma at the 2020 American Society of Clinical Oncology Virtual Meeting
5/15/2020
Data support the initiation of an upcoming first-in-human trial for first-line, MRD+ multiple myeloma patients post-ASCT
-
/C O R R E C T I O N -- EMD Serono/
5/14/2020
Two-year follow-up for first-in-class bifunctional immunotherapy bintrafusp alfa‡ targeting TGF-β/PD-L1, in second-line NSCLC
-
Tiziana Life Sciences Announces Data Demonstrating StemPrintER’s Superiority Compared to Oncotype DX in Providing Prognostic Informat to Conventional Clinical Parameters in Breast Cancer Patients in Poster Discussion Session at the ASCO
5/14/2020
Additional data to be presented validating the SPARE Model for Distant Metastasis Prediction utilizing the Company’s StemPrintER Platform
-
Sanofi to showcase oncology portfolio and innovative pipeline at ASCO20 Virtual Scientific Program
5/13/2020
New data for Sarclisa® (isatuximab-irfc) and Jevtana® (cabazitaxel) in difficult-to-treat cancers reinforce breadth and depth of portfolio